Prostate-Specific Antigen

Greater adherence to PSA screening reduced risk for metastatic and lethal prostate cancer among Black men aged 40 years to 55 years, according to results of an observational study presented during the virtual ASCO Annual Meeting.

U.S. states with larger declines in PSA screening from 2002 to 2016 also had larger increases in incidence of metastatic prostate cancer at diagnosis, according to a presentation at Genitourinary Cancers Symposium.

Rucaparib demonstrated antitumor activity among men with metastatic castration-resistant prostate cancer and a deleterious BRCA alteration, according to results of the phase 2 TRITON2 study published in Journal of Clinical Oncology.

New model estimates demonstrate the long-term benefits of prostate cancer screening and “suggest that the balance of benefits and harms of screening may be more favorable than is generally appreciated,” experts wrote in The New England Journal of Medicine.

PSA level prior to salvage radiotherapy may be a prognostic biomarker for clinical outcomes of long-term antiandrogen therapy with salvage radiotherapy among men with prostate cancer, according to results of a secondary analysis of a randomized trial published in JAMA Oncology.

Incidence of prostate cancer among adolescents and young adults has increased in the United States and many other countries during the past 3 decades, according to study results published in Cancer.

Men with prostate cancer with positive surgical margins or extracapsular extension achieved longer biochemical RFS after radical prostatectomy with adjuvant radiotherapy compared with surgery alone, according to results of a randomized Finnish study published in European Urology.